Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation.

In line with the previous observations, the difference in probability of recurrent CMV reactivation between patients with a positive or negative pp65-specific test result after the first reactivation was highly significant, both in the total population (HR 4.91; log-rank test, P <0.001) and in the D-/R+ group (HR 2.52; log-rank test, P =0.013) ( Figure 2D ).

also in 132,142 other papers